1
|
Lee A, James J, Whisker L, Rakha EA, Ellis IO. Which lesions with a radiological or core biopsy diagnosis of fibroadenoma should be excised? Ann R Coll Surg Engl 2021; 104:361-366. [PMID: 34939848 DOI: 10.1308/rcsann.2021.0208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
INTRODUCTION A recent Association of Breast Surgery summary statement on fibroadenoma management recommends excision only for cellular fibroepithelial lesions and rapidly growing lesions with a core biopsy diagnosis of fibroadenoma; persistent pain is a relative indication for excision. METHODS This retrospective study looked at the impact this approach would have on the diagnosis of phyllodes tumours. RESULTS From 2014 to 2018, there were 1,058 core biopsy diagnoses of fibroadenoma; 112 lesions were excised, of which 98 were fibroadenomas, 4 were hamartomas and 10 were phyllodes tumours. In this group, an excision diagnosis of phyllodes tumour was associated with size more than 40 mm, age more than 40 years and radiological suspicion of phyllodes tumour or carcinoma. One hundred and sixty-six excised fibroepithelial lesions with no previous core biopsy included eight phyllodes tumours; in this group, rapid growth was associated with phyllodes tumour diagnosis. Twelve of the 26 fibroepithelial lesions classified as B3 (cellular fibroepithelial lesion or phyllodes tumour) were diagnosed as phyllodes tumours on excision. Using a combination of radiological, clinical and pathological features it was possible to create an excision policy that would recommend excision of 22 of the 31 phyllodes tumours in this period. Eight of the nine 'missed' phyllodes tumours were benign. CONCLUSION The Association of Breast Surgery summary statement will reduce the number of fibroadenomas excised, but may also result in delayed diagnosis of some phyllodes tumours. Appropriate safety netting advice should be provided to identify rapidly growing lesions.
Collapse
Affiliation(s)
- Ahs Lee
- Nottingham University Hospitals NHS Trust, UK
| | - J James
- Breast Institute, Nottingham University Hospitals NHS Trust, UK
| | - L Whisker
- Breast Institute, Nottingham University Hospitals NHS Trust, UK
| | - E A Rakha
- Nottingham University Hospitals NHS Trust, UK
| | - I O Ellis
- Nottingham University Hospitals NHS Trust, UK
| |
Collapse
|
3
|
Rao R, Ludwig K, Bailey L, Berry TS, Buras R, Degnim A, Fayanju OM, Froman J, Golesorkhi N, Greenburg C, Ma AT, Mautner SK, Krontiras H, Sowden M, Wexelman B, Landercasper J. Select Choices in Benign Breast Disease: An Initiative of the American Society of Breast Surgeons for the American Board of Internal Medicine Choosing Wisely ® Campaign. Ann Surg Oncol 2018; 25:2795-2800. [PMID: 29968026 DOI: 10.1245/s10434-018-6584-5] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2018] [Indexed: 11/18/2022]
Abstract
BACKGROUND Up to 50% of all women encounter benign breast problems. In contrast to breast cancer, high-level evidence is not available to guide treatment. Management is therefore largely based on individual physician experience/training. The American board of internal medicine (ABIM) initiated its Choosing Wisely® campaign to promote conversations between patients and physicians about challenging the use of tests or procedures which may not be necessary. The American society of breast surgeons (ASBrS) Patient safety and quality committee (PSQC) chose to participate in this campaign in regard to the management of benign breast disease. METHODS The PSQC solicited initial candidate measures. PSQC surgeons represent a wide variety of practices. The resulting measures were ranked by modified Delphi appropriateness methodology in two rounds. The final list was approved by ASBrS and endorsed by the ABIM. RESULTS The final five measures are as follows. (1) Don't routinely excise areas of pseuodoangiomatous stromal hyperplasia (PASH) of the breast in patients who are not having symptoms from it. (2) Don't routinely surgically excise biopsy-proven fibroadenomas that are < 2 cm. (3) Don't routinely operate for a breast abscess without an initial attempt to percutaneously aspirate. (4) Don't perform screening mammography in asymptomatic patients with normal exams who have less than a 5-years life expectancy. (5) Don't routinely drain nonpainful, fluid-filled cysts. CONCLUSIONS The ASBrS Choosing Wisely® measures that address benign breast disease management are easily accessible to patients via the internet. Consensus was reached by PSQC regarding these recommendations. These measures provide guidance for shared decision-making.
Collapse
Affiliation(s)
- Roshni Rao
- Department of Surgery, Division of Breast Surgery, Columbia University Medical Center, New York, NY, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | - Michelle Sowden
- The University of Vermont Medical Center, Burlington, VT, USA
| | | | | |
Collapse
|